RNF166

Across TCGA pan-cancer cohorts, RNF166 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNF166 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNF166 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF166 expression acts as an unfavorable survival marker.

LUAD and KIRP are the cancer types where RNF166 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.147	0.812	<.001	36	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RNF166–LUAD (OS)

Open the LUAD breakdown →